Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, showing improved liquidity, lower operating expenses and progress in its clinical development program. The biopharmaceutical company, which focuses on neurodegenerative and metabolic disorders, said cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, for combined holdings of $12.22 million. That compares with $4.12 million at year-end 2025, excluding restricted digital assets, according to the www.newmediawire.com release.
The strengthened balance sheet matters because it gives Quantum runway to pursue its lead drug candidate without an immediate financing scramble. Shareholders’ equity increased 91% to $9.77 million, while working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. Quantum also reported a 21% reduction in operating cash use for the first nine months of 2026 and a decrease in notes payable to $300,000 following repayment of $1 million in debt. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months.
Beyond the numbers, the company disclosed a key operational step: after quarter-end, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. The agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. For investors and patients, the Thermo Fisher deal signals that the program is moving from regulatory clearance into trial execution, a phase that typically consumes significant capital and carries scientific risk.
Quantum, through wholly owned subsidiary Lucid Psycheceuticals Inc., is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, plus royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
For readers tracking early-stage biotech, the takeaway is that Quantum has paired cost discipline with a better-funded balance sheet ahead of a costly Phase 2 trial. The company’s digital asset holdings add a volatile component to its liquidity, but management’s 12-month runway assertion and the reduced cash burn suggest near-term financing pressure has eased. Full terms of use and disclaimers applicable to content provided by IBN are available at https://IBN.ai/Disclaimer, and the complete press release can be viewed at https://ibn.fm/GJ1ER. Additional company details are available through the Quantum BioPharma (NASDAQ: QNTM) profile.


